vs
Side-by-side financial comparison of REED'S, INC. (REED) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
STRATA Skin Sciences, Inc. is the larger business by last-quarter revenue ($9.3M vs $7.5M, roughly 1.2× REED'S, INC.). STRATA Skin Sciences, Inc. runs the higher net margin — 0.6% vs -50.5%, a 51.2% gap on every dollar of revenue. On growth, STRATA Skin Sciences, Inc. posted the faster year-over-year revenue change (-3.0% vs -23.1%). STRATA Skin Sciences, Inc. produced more free cash flow last quarter ($-551.0K vs $-3.9M). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs -11.7%).
Waddell & Reed Financial, Inc. was an American asset management and financial planning company founded in 1937 in Kansas City, Missouri. It was a publicly traded company from 1998 to 2021, and briefly had its headquarters in Overland Park, Kansas, and was planning a move back to Downtown Kansas City before the company was sold. It operated asset management and distribution subsidiaries, including Ivy Investment Management Company and Waddell & Reed Investment Management Company.
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
REED vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.5M | $9.3M |
| Net Profit | $-3.8M | $58.0K |
| Gross Margin | 20.4% | 61.8% |
| Operating Margin | -46.9% | 5.3% |
| Net Margin | -50.5% | 0.6% |
| Revenue YoY | -23.1% | -3.0% |
| Net Profit YoY | 8.2% | 101.3% |
| EPS (diluted) | $-1.26 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.5M | $9.3M | ||
| Q3 25 | $7.0M | $6.9M | ||
| Q2 25 | $9.5M | $7.7M | ||
| Q1 25 | $10.0M | $6.8M | ||
| Q4 24 | $9.7M | $9.6M | ||
| Q3 24 | $6.8M | $8.8M | ||
| Q2 24 | $11.9M | $8.4M | ||
| Q1 24 | $9.6M | $6.8M |
| Q4 25 | $-3.8M | $58.0K | ||
| Q3 25 | $-4.0M | $-1.6M | ||
| Q2 25 | $-6.0M | $-2.6M | ||
| Q1 25 | $-2.0M | $-2.1M | ||
| Q4 24 | $-4.1M | $-4.6M | ||
| Q3 24 | $-4.2M | $-2.1M | ||
| Q2 24 | $-3.2M | $-91.0K | ||
| Q1 24 | $-1.7M | $-3.4M |
| Q4 25 | 20.4% | 61.8% | ||
| Q3 25 | 17.4% | 60.4% | ||
| Q2 25 | 8.5% | 56.2% | ||
| Q1 25 | 33.9% | 53.5% | ||
| Q4 24 | 30.0% | 61.4% | ||
| Q3 24 | 18.0% | 60.1% | ||
| Q2 24 | 32.3% | 59.0% | ||
| Q1 24 | 35.6% | 45.6% |
| Q4 25 | -46.9% | 5.3% | ||
| Q3 25 | -58.3% | -16.9% | ||
| Q2 25 | -60.8% | -30.1% | ||
| Q1 25 | -17.4% | -25.0% | ||
| Q4 24 | -37.6% | -44.7% | ||
| Q3 24 | -46.5% | -18.2% | ||
| Q2 24 | -5.6% | -5.7% | ||
| Q1 24 | -6.8% | -42.7% |
| Q4 25 | -50.5% | 0.6% | ||
| Q3 25 | -56.6% | -23.4% | ||
| Q2 25 | -63.5% | -33.6% | ||
| Q1 25 | -20.3% | -31.2% | ||
| Q4 24 | -42.3% | -47.6% | ||
| Q3 24 | -61.5% | -23.6% | ||
| Q2 24 | -27.1% | -1.1% | ||
| Q1 24 | -17.4% | -49.8% |
| Q4 25 | $-1.26 | $0.14 | ||
| Q3 25 | $-0.48 | $-0.36 | ||
| Q2 25 | $-0.13 | $-0.62 | ||
| Q1 25 | $-0.04 | $-0.51 | ||
| Q4 24 | $-3.73 | $-2.01 | ||
| Q3 24 | $-4.91 | $-0.51 | ||
| Q2 24 | $-0.77 | $-0.03 | ||
| Q1 24 | $-0.40 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $7.9M |
| Total DebtLower is stronger | — | $15.3M |
| Stockholders' EquityBook value | $9.2M | $2.9M |
| Total Assets | $23.3M | $30.5M |
| Debt / EquityLower = less leverage | — | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $7.9M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | — | $6.0M | ||
| Q1 25 | — | $6.5M | ||
| Q4 24 | — | $7.3M | ||
| Q3 24 | — | $7.1M | ||
| Q2 24 | — | $5.5M | ||
| Q1 24 | — | $5.2M |
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | $9.2M | $2.9M | ||
| Q3 25 | $2.8M | $1.3M | ||
| Q2 25 | $1.7M | $532.0K | ||
| Q1 25 | $4.7M | $3.0M | ||
| Q4 24 | $6.6M | $5.0M | ||
| Q3 24 | $-22.0M | $9.4M | ||
| Q2 24 | $-23.8M | $9.5M | ||
| Q1 24 | $-20.7M | $9.4M |
| Q4 25 | $23.3M | $30.5M | ||
| Q3 25 | $19.9M | $30.7M | ||
| Q2 25 | $23.7M | $29.5M | ||
| Q1 25 | $24.5M | $33.0M | ||
| Q4 24 | $25.1M | $34.9M | ||
| Q3 24 | $15.0M | $39.4M | ||
| Q2 24 | $18.7M | $38.8M | ||
| Q1 24 | $19.3M | $39.2M |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.8M | $-239.0K |
| Free Cash FlowOCF − Capex | $-3.9M | $-551.0K |
| FCF MarginFCF / Revenue | -52.0% | -5.9% |
| Capex IntensityCapex / Revenue | 1.1% | 3.4% |
| Cash ConversionOCF / Net Profit | — | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | $-17.3M | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.8M | $-239.0K | ||
| Q3 25 | $-2.8M | $-64.0K | ||
| Q2 25 | $-5.0M | $-1.9M | ||
| Q1 25 | $-5.4M | $-550.0K | ||
| Q4 24 | $-3.9M | $703.0K | ||
| Q3 24 | $1.1M | $-302.0K | ||
| Q2 24 | $-912.0K | $591.0K | ||
| Q1 24 | $-2.4M | $-804.0K |
| Q4 25 | $-3.9M | $-551.0K | ||
| Q3 25 | $-2.9M | $-1.1M | ||
| Q2 25 | $-5.1M | $-2.0M | ||
| Q1 25 | $-5.4M | $-749.0K | ||
| Q4 24 | $-4.0M | $199.0K | ||
| Q3 24 | $1.0M | $-364.0K | ||
| Q2 24 | $-924.0K | $246.0K | ||
| Q1 24 | $-2.4M | $-1.5M |
| Q4 25 | -52.0% | -5.9% | ||
| Q3 25 | -41.5% | -15.6% | ||
| Q2 25 | -53.2% | -26.1% | ||
| Q1 25 | -54.2% | -11.0% | ||
| Q4 24 | -40.8% | 2.1% | ||
| Q3 24 | 15.3% | -4.1% | ||
| Q2 24 | -7.8% | 2.9% | ||
| Q1 24 | -25.1% | -22.6% |
| Q4 25 | 1.1% | 3.4% | ||
| Q3 25 | 1.4% | 14.7% | ||
| Q2 25 | 0.2% | 0.8% | ||
| Q1 25 | 0.7% | 2.9% | ||
| Q4 24 | 1.0% | 5.3% | ||
| Q3 24 | 0.3% | 0.7% | ||
| Q2 24 | 0.1% | 4.1% | ||
| Q1 24 | 0.2% | 10.7% |
| Q4 25 | — | -4.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
REED
Segment breakdown not available.
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
